Executives from Eli Lilly, Novo Nordisk and Sanofi, as well as representatives from the three largest pharmacy benefit managers, will testify before the House Energy and Commerce Committee’s Subcommittee on Oversight and Investigations April 10; patients, professional organization representatives and academics at an April 2 hearing said they want to know why insulin prices remain out of reach for many diabetics.
Insulin manufacturers can expect to face questions about their pricing practices, supply chain negotiations and adequacy of their patient assistance programs when they appear before a US House subcommittee April 10.
Representatives from Eli Lilly & Co., Novo Nordisk AS and Sanofi will testify before the House Energy...
Doctors are increasingly falling victim to financial scams due to their high incomes, busy schedules, and trust in professional networks. Recognizing the tactics scammers use and the reasons behind physicians’ susceptibility is essential for protecting medical professionals.
Senate HELP Committee chair Sanders trying to broker a deal between Novo Nordisk and the major pharmacy benefit managers that will lead to lower list prices.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
An effort to change the US Food and Drug Administration’s conclusion that its obesity treatment candidate retatrutide is a drug and not a biologic could give the product more time with unrestricted pricing in Medicare, among other benefits.
Pharmacy benefit manager sues Federal Trade Commission claiming chair Khan has orchestrated a campaign against PBMs that is not based in fact.
Alternatives to the top pharmacy benefits managers argue health plan-PBM integration is leading to anti-competitive tactics that make it impossible for some employers to switch PBMs.
The UK regulator approved 16 medicines containing a new active substance in the first half of this year, while the European Commission issued marketing authorizations for 20 NAS-containing drugs.
